RT info:eu-repo/semantics/article
T1 HMG CoA Reductase Inhibitors and Impotence Two Case Series from the Spanish and French Drug Monitoring Systems
A1 Carvajal García-Pando, Alfonso
A1 Macías, Diego
A1 Sáinz Gil, María
A1 Ortega, Sara
A1 Martín Arias, Luis Hermenegildo
A1 Velasco Martín, Alfonso
A1 Bagheri, Haleh
A1 Lapeyre-Mestre, Maryse
A1 Montastruc, Jean Louis
K1 Medicamentos - Efectos secundarios
K1 Impotencia sexual
AB Objective: HMG CoA Reductase inhibitors, more commonly called statins, areused in the pharmacological management of hyperlipidaemia. At present, the useof these drugs is increasing worldwide. They have been linked to certain adversedrug reactions, including impotence. The aim of the present study is to explore thebasis of the association between statin use and impotence using data fromspontaneous reports.Method: We analysed the cases of impotence associated with statins that werecollected by the Spanish and French pharmacovigilance systems. We used casesof impotence as a numerator and consumption data as a denominator to estimatethe cumulative reported incidence of impotence.Results: Thirty-eight cases of impotence associated with statins have beenidentified in the database of the Spanish pharmacovigilance system; overall, therewas a temporal sequence of events in all cases and the adverse reaction disappearedafter drug withdrawal in 93% of the cases. Sixteen patients had also beentreated with other drugs. In France, 37 cases were collected. In 85% of these casesrecovery from the adverse reaction was observed after drug withdrawal; there wasa positive rechallenge in five cases, and 15 patients were receiving other drugs atthe same time. No significant differences among reported incidences with differentstatins were found.Conclusion: Considering the widespread use of this drug class and the under-reportingof this particular reaction it could affect a large number of patients. Thereaction seems to be reversible in most of the cases after drug withdrawal. Doctorsshould be aware of this potential adverse reaction when prescribing statins to theirpatients.
PB Springer Verlag
SN 0114-5916
YR 2006
FD 2006
LK http://uvadoc.uva.es/handle/10324/9056
UL http://uvadoc.uva.es/handle/10324/9056
LA eng
NO Drug Safety, 2006; 29 (2): 143-149
NO Producción Científica
DS UVaDOC
RD 16-abr-2024